IP Verse

Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer

Patent No. EP3177645 (titled "Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer") was filed by Lindhofer on Aug 10, 2015. The application was issued on Feb 17, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ABBVIENov 17, 2021MEWBURN ELLIS
DR H ULRICH DORRIESNov 17, 2021DORRIES
DR H ULRICH DORRIESNov 17, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMAN
GENMABNov 17, 2021J A KEMP
LAVA THERAPEUTICSNov 17, 2021COOLEY UK
MORPHOSYSNov 17, 2021SPILLER
BOEHRINGER INGELHEIMNov 16, 2021HOFFMANN EITLE
JAMES POOLENov 16, 2021CARPMAELS & RANSFORD
F HOFFMANN LA ROCHE GENENTECHNov 15, 2021MEWBURN ELLIS
REGENERON PHARMACEUTICALSMay 26, 2021CARPMAELS & RANSFORD
JANSSEN BIOTECHMar 16, 2021CARPMAELS & RANSFORD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3177645

LINDHOFER
Application Number
EP15756110A
Filing Date
Aug 10, 2015
Status
Revoked
Feb 16, 2024
Publication Date
Feb 17, 2021
External Links
Slate, Register , Google Patents